Tumor necrosis factor alpha-induced NF-kappaB signaling (TNF-NF-kB)

Tumor necrosis factor alpha (TNF-alpha)-induced NF-kappaB signaling is a fundamental proinflammatory pathway that coordinates the body's response to injury and infection. The process begins when the cytokine TNF-alpha binds to its cell surface receptors, TNFR1 or TNFR2, triggering a complex intracellular signaling cascade (Source: UniProt P01375). This cascade leads to the activation of the IkappaB kinase (IKK) complex, which phosphorylates IkappaB proteins, leading to their degradation and the subsequent release of the NF-kappaB transcription factor (Source: PMID: 12748582). Once liberated, NF-kappaB translocates to the nucleus to drive the expression of genes involved in inflammation, cell survival, and immune regulation (Source: PMID: 10891884). Dysregulation of this signaling axis is a key driver in chronic inflammatory conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, as well as in various cancers where it promotes tumor cell survival (Source: PMID: 16751774). Therapeutic strategies include the use of monoclonal antibodies to neutralize TNF-alpha or small molecules to inhibit downstream components like the proteasome (Source: FDA Drug Labels).

Other names

TNF-alpha signalingNF-kappaB activation pathwayTNF-TNFR-NFkB axisTumor necrosis factor-mediated NF-kappaB activation

Drugs targeting this pathway primarily function by neutralizing the TNF-alpha ligand, thereby preventing its interaction with TNFR1 and TNFR2 receptors and subsequent downstream NF-kappaB activation (Source: PMID: 21244308). Other agents, such as proteasome inhibitors, prevent the degradation of IkappaB, which sequesters NF-kappaB in the cytoplasm and inhibits its transcriptional activity (Source: PMID: 15128704).